Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Emerging nanodelivery strategies of RNAi molecules for colon cancer therapy: preclinical developments.

Binkhathlan Z, Alshamsan A.

Ther Deliv. 2012 Sep;3(9):1117-30. Review.

PMID:
23035595
2.
3.

In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi.

Xiao H, Wu Z, Shen H, Luo AL, Yang YF, Li XB, Zhu DY.

Basic Clin Pharmacol Toxicol. 2008 Oct;103(4):342-8. doi: 10.1111/j.1742-7843.2008.00296.x.

4.

Pharmacological strategies for overcoming multidrug resistance.

Nobili S, Landini I, Giglioni B, Mini E.

Curr Drug Targets. 2006 Jul;7(7):861-79. Review.

PMID:
16842217
5.
6.

Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.

Shapira A, Livney YD, Broxterman HJ, Assaraf YG.

Drug Resist Updat. 2011 Jun;14(3):150-63. doi: 10.1016/j.drup.2011.01.003. Epub 2011 Feb 16. Review.

PMID:
21330184
7.

Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics.

Kobayashi H, Takemura Y, Miyachi H.

Hum Cell. 2001 Sep;14(3):172-84. Review.

PMID:
11774737
8.

Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.

Dönmez Y, Gündüz U.

Biomed Pharmacother. 2011 Mar;65(2):85-9. doi: 10.1016/j.biopha.2010.12.007. Epub 2010 Dec 30.

PMID:
21237614
9.

Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo.

Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, Ding Y, Chen LM, Yang XP, Fu LW.

Cancer Biol Ther. 2006 Jan;5(1):39-47. Epub 2006 Jan 12.

PMID:
16319528
10.

P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.

Breier A, Barancík M, Sulová Z, Uhrík B.

Curr Cancer Drug Targets. 2005 Sep;5(6):457-68. Review.

PMID:
16178819
11.

Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells.

Abbasi M, Lavasanifar A, Berthiaume LG, Weinfeld M, Uludağ H.

Cancer. 2010 Dec 1;116(23):5544-54. doi: 10.1002/cncr.25321. Epub 2010 Aug 16.

12.

Prospects of RNA interference therapy for cancer.

Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC.

Gene Ther. 2006 Mar;13(6):464-77. Review.

PMID:
16341059
13.
14.

Overcoming multidrug resistance by RNA interference.

Stege A, Krühn A, Lage H.

Methods Mol Biol. 2010;596:447-65. doi: 10.1007/978-1-60761-416-6_20.

PMID:
19949936
15.

Can flavonoids from honey alter multidrug resistance?

Jaganathan SK.

Med Hypotheses. 2011 Apr;76(4):535-7. doi: 10.1016/j.mehy.2010.12.011. Epub 2011 Jan 17.

PMID:
21247706
16.
17.

Gene therapy for colon cancer.

Zwacka RM, Dunlop MG.

Hematol Oncol Clin North Am. 1998 Jun;12(3):595-615. Review.

PMID:
9684100
18.

Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.

Yadav S, van Vlerken LE, Little SR, Amiji MM.

Cancer Chemother Pharmacol. 2009 Mar;63(4):711-22. doi: 10.1007/s00280-008-0790-y. Epub 2008 Jul 11.

PMID:
18618115
19.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
20.

Supplemental Content

Support Center